Genzyme and Fovea Pharmaceuticals SA have entered into a collaborative research pact centered on Fovea’s proprietary high content technology platform that allows the identification of new targets involved in photoreceptor degeneration in retinal dystrophies. The companies will collaborate to develop gene-related therapies using Fovea’s selected targets and Genzyme’s gene delivery technologies. Fovea’s scientific, clinical and pharmaceutical expertise in retinal disease...